Tuhura Biosciences Inc (HURA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access HURA quarterly Cash Flow →
Cash flow data covering Tuhura Biosciences Inc–Jun 30 2021 offers a view into how Dec 31 2025's cash position has developed alongside business activity.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
12 Months
(Dec 31 2024) (Jun 30 2023) (Jun 30 2022) (Jun 30 2021)
Operating Activities
Income-30.06
Depreciation & amortization0.07
Amortization of Other Assets0.48
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation6.61
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Interest Expense Debt-
Gain Loss On Derivative Instruments Net Pretax-
Issuance Of Shares For Future Royalty Reduction-
Units Issued For Services-
Warrants Issued For Patents-
Prototype Drug Product-
Net Income Loss After Adjustments Of Non Cash Items-
Change In Fair Value Of Derivative Liability Due To Change In Warrant Terms-
Issuance Of Stock For Services-
In Progress Research And Development Expense-
Gain Loss From Change In Fair Value Of Milestone Liability-
Interest Expense-
Write Off Of In Process R And D-
Change In Fair Value Of Derivative Liability0.31
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities-3.76
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital-0.61
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-27.63
Investing Activities
Capital Expenditures-0.08
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Finite Lived Intangible Assets Period Increase Decrease-
Payments To Acquire Assets-
Payments For Deposits In Planned Business Acquisition-5.99
Payments For Deposits And Advances Planned Business Acquisition-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Business Two, Net of Cash Acquired-1.26
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.34
Financing Activities
Short-term debt Net3.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-1.93
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock20.37
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.50
Other net0.00
Net Proceeds From Issuance Of Units-
Proceeds From Issuance Of Shares And Warrants-
Deferred Financing Costs-
Payment Of Net Liabilities Assumed In Reverse Recapitalization-0.80
Payments of Ordinary Dividends, Preferred Stock and Preference Stock-0.01
Dividends paid0.00
Net Cash Flow from Financing Activities19.93
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-27.71
Total Cash Flow-9.04
4 historic quarters locked

Sign in to unlock the full Tuhura Biosciences Inc cash flow history.

About Tuhura Biosciences Inc Nv Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-134950

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License